Background: Mortality prediction models are useful in pediatric intensive care units (PICUs) as risk assessment tools and as a benchmark for the quality of care. Objectives: To assess the performance of the Pediatric Index of Mortality 2 (PIM2) in terms of calibration and discrimination between survivors and non-survivors among pediatric patients. Methods: This is a cohort prospective study including 317 pediatric patients admitted to two PICU settings in a tertiary care hospital in Egypt over a period of one year (from June 2012 till June 2013). Collected data included personal characteristics, hospital data, diagnosis, outcome and variables included in PIM2 scoring. Results: Non-survivors constituted 8.5%. Most common diagnosis was respiratory diseases (47.9%). Only CNS morbidities (11.7% of survivors versus 37% of non-survivors, P = 0.001) and a higher PIM2 score (2.39 ± 5.49 in survivors versus 41.38 ± 36.06 in non-survivors, P = 0.001) were associated with increased risk of non-survival. The area under the curve (AUC) for PIM2 is 0.796 (95% CI 0.675-0.916), P < 0.001. The Hosmer-Lemeshow goodness-of-fit was 2.850, 8 df, P = 0.943. PIM2. Conclusion: The calibration and the discriminative ability of PIM2 scoring system aiming to distinguish survivors from non-survivors are satisfactory for this sample of pediatric patients. PIM2 is easily calculated and is freely available. Thus, this tool provides a good incentive for ICU settings in Egypt for admission of high risk patients in the light of the limited PICU bed complement capacity in relation to the demands.
Introduction
Mortality rate of patients admitted to Pediatric Intensive Care Units (PICUs) is a widely recognized outcome indicator and was reported to vary from 3.8% to 13% worldwide. 1 Several scoring models that predict the risk of mortality of pediatric patients admitted to the intensive care are available. 2, 3 Mortality prediction models are useful in PICU settings as risk assessment tools and as a benchmark for the quality of care between facilities. 4 Prediction tools must discriminate well between survivors and non-survivors and be well calibrated before they can be applied usefully to assess or standardize comparisons of PICUs or to correct for case-mix differences between groups in observational studies. 5 Pediatric Index of Mortality (PIM) was first developed in 1997 6 and as most other prognostic scoring systems, was upgraded to PIM2, which was observed to have better predictability of the outcome of pediatric patients admitted to intensive care. 7 PIM2 score is usually applied at the time of admission to intensive care, unlike other prognostic scores which can be calculated at time intervals throughout the patient's stay in intensive care. 7 Several studies have documented PIM2 as a suitable risk assessment tool for prediction of mortality among pediatric patients, being the most accurate among several models, and having the best fit in different diagnostic and risk groups. 8 It is recent, freely available while many other rating tools need a license and in addition, PIM2 has a small number of variables, thus it is easily calculated. 4, 9 We aimed in the current study to assess the performance of PIM2, in terms of discriminatory ability and calibration in a sample of Egyptian children admitted to the PICU.
Materials and methods

Study design and study settings
This is a prospective observational study. The study settings are two medical Pediatric Intensive Care Units (PICUs) at the Pediatric Hospital (Abu El-reesh), a tertiary care pediatric hospital affiliated to the Kasr Al-Ainy school of Medicine, Cairo University and is considered the largest free pediatric hospital in Egypt and the Middle East. The bed complement capacity of each of the PICUs is 20 beds and is staffed by full-time specialized pediatricians and residents with 24 h/day coverage. Patients are admitted to the PICU from the Emergency Department directly or from the general wards. The hospital includes radiology and pathology departments and clinical pathology laboratories and the PICUs have state-ofthe-art equipment enabling the performance of a wide variety of investigations such as facilities for blood gas analyses, portable radiograph and ultrasound.
Study participants and data collection
Data were prospectively collected for 317 pediatric patients admitted to the selected units over a period of one year (from June 2012 till June 2013). Collected data at admission included age, sex, weight, diagnosis, LOS in the PICU, PICU survival and items included in PIM2 scoring namely; the systolic blood pressure, pupillary reactions to bright light, partial oxygen tension (PaO2) and FIO2 at the time of PaO2 if oxygen is given via ETT or headbox, base excess in arterial or capillary blood, mechanical ventilation at any time during the first hour of PICU admission, elective admission to ICU, whether recovery from surgery or a procedure is the main reason for ICU admission, whether the patient is admitted following cardiac bypass, presence of high risk diagnosis. Definitions concerning these variables and the scoring method were according to PIM2 developers' guidelines. 7 PIM2 score was calculated using an online PIM2 calculator 10 based on the regression equation published in the PIM-2 scoring system manual. 7 Table 1 Characteristics of the studied group and comparison between survivors and non survivors by demographic characteristics, diagnosis, length of stay (LOS) and Pediatric Index of Mortality 2 (PIM2) score. As PIM2 is calculated from the information collected at the time a child is admitted to the intensive care, PIM2 algorithm is calculation of PIM2 (and PIM2 risk of death%) À PIM2 val = (0.01395 * (absolute (SBP-120))) + (3.0791 * Pupils) + (0.2888 * (100 * FiO2/PaO2)) + (0.1040 * (absolute Base Excess)) + (1.3352 * MechVent) À (0.9282 * Elective) À (1.0244 * Recovery) + (0.7507 * Bypass) + (1.6829 * HRdiag) À (1.5770 * LRdiag) À 4.8841. The PIM2 risk of death = exp PIM2 val/ (1 + expPIM2 val). For example, if a patient at the time of admission has a recorded systolic blood pressure of 55 mmHg, PaO2 of 110 mmHg, FiO2 0.5, base excess À6.0 the pupils are reactive to light. Thus PIM2 val = (0.01395 * [absolute (55-120)) + (3.0791 * 0) + (0.2888 * (100 * 0.5/110)) + (0.104 * |À6.0|) + (1.3352 * 1) À (0.9282 * 1) À (1.0244 * 1) + (0.7507 * 1) + (1.6829 * 1) À (1.5770 * 0) À 4.8841 = À1.4059. The probability of Death = exp (À1.4059)/[1 + exp (À1.4059)] = 0.1969 or 19.7%. 7
Statistical analysis
Statistical analysis was performed using SPSS software version 17 (SPSS Inc., Chicago, IL, USA). Descriptive statistics was displayed as frequencies and percentages for categorical variables. The median and interquartile range (IQR) was used to summarize continuous variables which are not normally distributed when examined by the Kolmogorov-Smirnov test and histogram plotting. The Chi squared test was used to compare categorical variables and the Mann-Whitney U-test was used to test significant differences of continuous variables among survivors and non-survivors and for PIM2 score; the student t-test of significance was used. To assess the overall performance of PIM2, Nagelkerke's R 2 statistic is calculated using logistic regression analysis. Nagelkerke's R 2 is calculated for survival outcomes, based on the difference in 2 log likelihood of a model without and a model with at least one predictor 11 and this predictor in the current study is the PIM2 score. Receiver Operating Characteristic (ROC) curve analysis was performed to analyze the discriminatory ability of PMI2 score to distinguish between survivors and non-survivors. Acceptable discrimination is represented by a concordance ''c'' statistic, also known as an Area under the Curve (AUC) of 0.70-0.79, and a good discrimination by an AUC of P0.80, and excellent by an AUC P0.9. 12 The Hosmer-Lemeshow goodness-of-fit analysis was performed to calibrate PIM2. Calibration refers to the agreement between observed and expected (predicted) outcomes. Model for which expected and observed event rates are similar is called well calibrated and this is across different subgroups (deciles) of fitted risk values. Acceptable calibration is evidenced by a P value >0.05. 13 Patients were grouped by age, sex and diagnosis in order to assess PIM2 performance across these subgroups as well in terms of calibration and discrimination. Standardized Mortality Ratio (SMR) (The ratio of the observed to the expected mortality) and 95% CI were calculated for the whole group and for subgroups of patients using the OpenEpi statistical calculator online. 14 If the upper 95% CI of the SMR is <1, then observed mortality is regarded as being lower than the expected. 4 The outcome of interest is dichotomous, either survival (the patient is discharged alive from the PICU) or non-survival (the patient died during his stay in the PICU). Statistical significance was set at P 6 0.05. 
Results
The studied group consisted of 317 children admitted to the selected PICUs. Table 1 demonstrates that males constituted 50.5% of the subjects. The median age was 14 (6-30) months. Non-survivors constituted 8.5% of the studied group. Most common diagnosis was respiratory diseases followed by cardiovascular morbidities. As regards patients admitted with metabolic disorders, the treating physicians' preliminary diagnosis was ''metabolic disease for investigation'' and these include tyrosinemia, glycogen storage disease and biotin deficiency disease. It is observed as well from Table 1 that non-survivors had a higher percentage of sepsis (11.1%) compared to survivors (7.6%), however this difference was statistically insignificant (P = 0.46). Only CNS morbidities and a higher PIM2 score were significantly associated with increased risk of non-survival. The ROC curve for the overall studied group is illustrated in Fig. 1 . The value of the AUC was 0.796 with a 95% CI of 0.675-0.916, P < 0.001 indicating a good discriminatory ability between survivors and non-survivors.
Observed and expected mortalities across deciles of risk of non-survival according to the Hosmer-Lemeshow test is shown in Table 2 . It revealed a good calibration for PIM2 as the differences between observed and expected mortalities across all deciles of mortality risk were statistically insignificant. SMR for each decile of risk was calculated and revealed that PIM2 predicted mortalities for the whole group of patients were correct in nearly all deciles, slightly lower mortalities were predicted in some deciles of risk (2, 8 and 9) while a higher mortality was predicted by PIM2 in the 7th decile of mortality risk, where no actual mortalities were observed. Table 3 demonstrates that the difference between observed and PIM2 expected mortality across risk deciles was statistically insignificant (Hosmer-Lemeshow x 2 is 2.850, df = 8, P = 0.943) indicating a good calibration of PIM2 across these deciles. Nagelkerke's R 2 is 0.50 indicating that 50% of mortalities can be predicted by PIM2 score solely. Further in-depth analyses were performed to determine the validity of PIM2 score among subgroups of patients, by age, sex, weight, LOS and diagnosis (Tables 3 and 4 ). The Hosmer-Lemeshow goodness of fit test showed no significant differences between observed mortalities and PIM2 expected mortalities across subgroups of patients, except for patients diagnosed having metabolic disorders or those with miscellaneous morbidities where no observed deaths were recorded in these 2 subgroups. The ROC curve analysis showed a good discriminatory ability of PIM2 score to distinguish between survivors and non-survivors across all subgroups of patients except for those with a hospital LOS of more than 6 days where the AUC is 0.63, 95% CI 0.38-0.89, P = 0.14, indicating poor discrimination between survivors and non-survivors in this subgroup of patients. This poor performance in this particular group of patients is further illustrated in Table 4 , where PIM2 predicted only 20% of observed mortalities among those patients with a LOS more than 6 days.
It is illustrated in Table 4 that the SMR for the patients' case-mix is 1.92 (95% CI, 1.29-2.76) indicating that PIM2 predicted mortality (4.41%) was less than the observed one (8.5%). PIM2 predicted 51.9% of the observed mortalities among all patients. For survivors, PIM2 predicted 99.3% of the observed survivals. This observation was true for PIM2 predicted mortalities among all subgroups of patients displayed in Table 4 but the difference between the observed 
Discussion
The current study investigated 317 subjects admitted to the PICUs in a large tertiary care hospital in Egypt, aiming to assess the performance of PIM2, in terms of discriminatory ability and calibration. The general characteristics of the studied subjects, such as nearly equal proportions of males and females, most common diagnosis on admission; being respiratory morbidities and the median LOS of the studied group in the PICU are comparable to similar studies investigating the validity of PIM2 in PICUs in developing countries 15 except for the median age of the subjects in the current study which was 14 months, while in the study by Hariharan et al., 2011 the mean age of the subjects was 4.9 ± 4.4 years. 15 The overall performance of PIM2 in PICU settings in this sample of Egyptian population is good. For all patients, PIM2 has a good calibration as there is an agreement between the observed and PIM2 expected mortalities for the studied population (Hosmer-Lemeshow v 2 is 2.850, 8 df, P = 0.943) and it fits similarly quite well across all risk categories. This finding is consistent with many other studies. A multicenter prospective study in ICU settings in Italy reported a similar good calibration of PIM2 for case-mix (Hosmer-Lemeshow v 2 is 9.86; 8 df, P = 0.26) for the whole population and across all deciles of risk. 9 In Korea, a retrospective study identified a good calibration of PIM2 among pediatric patients admitted to intensive care (Hosmer-Lemeshow v 2 = 14.986; P = 0.308). 16 The present study demonstrates as well a good discriminatory ability of PIM2 to differentiate survivors from non-survivors (AUC 0.796, 95% CI 0.675 to 0.916, P < 0.001). This observation is in agreement with many studies. A prospective study in five PICU settings in the UK documented a good discrimination of PIM2 model (AUC 0.84, 95% CI 0.819 to 0.853). 17 In Japan, PIM2 proved excellent discrimination in a prospective cohort study including 2536 children admitted to the largest PICU, where the AUC value was 0.92 (95% CI 0.89-0.96). 4 In India, PIM2 discriminated well between survivors and non-survivors admitted to a tertiary hospital in India with AUC 0.843 (95% CI 0.76-0.90). 18 An AUC of 0.75 or more is usually considered clinically useful. In the current study, an AUC of 0.79 means that a randomly selected nonsurvivor would have a higher PIM2 score than a randomly selected survivor 79% of the time; it does not mean that prediction of death is correct 79% of the time. 17 Across subgroups of patients, PIM2 shows a good discriminatory ability as evident by an AUC of at least 0.70 (0.48-0.93) for the group of patients diagnosed having respiratory illnesses, except for the group of patients with LOS >6 days, where ROC curve analysis showed an AUC of 0.63 (95% CI 0.38-0.89), P = 0.14 was observed.
Many studies investigating the validity of PIM2 in PICU settings report an observed mortality lower than the PIM2 predicted mortality and thus an SMR less than 1. In the study of Hariharan et al., 2011 conducted in Barbados the observed mortality was found to be 5.5%; lower than the PIM2 predicted mortality (6.2%), SMR is 0.89. 15 A prospective study of PIM2 performance in 3 Italian PICUs and one cardiac intensive care unit reported an observed mortality of 4.4% and a predicted mortality of 6.4%, SMR is 0.7 (95% CI 0.6-0.8). 1 In Argentina, a prospective cohort study documented an observed mortality of 2.6% in PICU compared to a PIM2 predicted mortality of 3.06%. 19 A cohort study among children admitted to three PICU settings in Hong Kong revealed a PIM2 predicted mortality (14.2 deaths) compared to 7 observed deaths, SMR is 0.49 (95% CI 0.13 to 0.86). 20 In contrast to these reports, it is remarkable in the current study that a difference exists between the observed (8.5%) and the PIM2 predicted (4.4%) mortalities for the case-mix of patients (SMR 1.92; 95% CI 1.29-2.76). This finding is detected as well across subgroups of patients particularly, those aged 612 months, females, those with respiratory morbidities, and those staying in the PICU for >6 days. While for survivors, agreements between observed and expected survivors ranged from 98% up to 100%. It may be suggested that PIM2 model has a greater ability to correctly predict survival rather than non-survival in this case-mix of Egyptian children. Pearson et al., 2001 discussed this controversy and they claimed that when observed mortalities are higher than the predicted; either there is poor model performance or poor clinical performance and that clinical interpretation concerning this is rarely objective. 17 Taking into consideration the good calibration and discrimination of the model across risk categories displayed in Table 2 , it is suggested that such differences between observed and PIM2 predicted mortalities may be due to confounders such as the differences in the population under study compared to the original population in which PIM2 was first investigated and developed, or due to inadequate resources or a small number of included subjects that may be a limitation. The SMR in the present study is 1.92 (95% CI 1.29-2.76) and commonly an SMR more than 1 may be suggestive of a poor quality of care similarly, according to Pearson et al., 2001. 17 Some researchers responded to such a high SMR in their PICU settings upon assessing PIM2 performance by changing the coefficients of the original model to compensate for the inadequate clinical performance, but this is considered inappropriate by the developers of this prediction tool. 17 In accordance with the present study, similar studies, particularly in developing countries have reported results similar to that of the current study concerning an overall observed mortality that is higher than the PIM2 predicted mortality with a subsequent SMR of more than one. In a study including 1823 children admitted to the PICU of the Hospital de Clinicas de Porto Alegre, the observed mortality was 10.3%. On the other hand, PIM2 predicted mortality was 6.5%. 21 In Iran, a prospective cohort study to validate PIM2 performance in a tertiary hospital in Tehran, the observed mortalities among children admitted to the PICU reached 15%, while PIM2 predicted mortality was 8.3%, SMR is 1.8 (95% CI 1.28-2.46). 22 Of the limitations of the study is that it is hospital-based, thus the observed mortality rate of 8.4% cannot be generalized to represent children's mortalities admitted to PICUs all over Egypt.
It is concluded that the calibration and the discriminative ability of PIM2 scoring system aiming to distinguish survivors from non-survivors are satisfactory. PIM2 predicted mortality for this case-mix of Egyptian children admitted to the PICU is lower than the observed mortality and the standardized mortality ratio is greater than 1. PIM2 is easily calculated and is freely available, thus provides a good incentive for ICU settings in Egypt for admission of high risk patients in the light of the limited PICU bed complement capacity in relation to the demands.
